🇫🇮 Voima Ventures strengthens life science expertise and presence in Sweden
Voima Ventures is pleased to welcome Stina Wallmark as our new Life Sciences Investment Director, enhancing our commitment to impactful biotech and healthcare innovations. Based in Sweden, Stina will help drive Voima Venture’s focus on emerging technologies that address global health and societal challenges across the Nordics and Baltics.
Stina brings a wealth of knowledge from her career, including 15 years in various operational roles in the Life Sciences and Healthcare industry with GE Healthcare and Cytiva. As an Investment Manager at Almi Invest for the last three years, she has worked on building startups and scaleups with cutting-edge biotech solutions, positioning her as a key figure in identifying promising startups in the life sciences field across the Nordic and Baltics.
“At Voima Ventures, our mission is to scale solutions that benefit people, the planet, and industries,” says Inka Mero, Voima Ventures’ Founder and Managing Partner. “As a leader in European deep tech VC, we prioritise diversity and impact within our team and across our portfolio. The Nordic life sciences and health tech sectors are thriving, with top entrepreneurial teams translating science into solutions for pressing global challenges like depression and cancer. We’re investing at the forefront of synthetic biology, precision therapies, personalised medicine, predictive diagnostics, and AI-driven innovations,” she adds. “I am extremely pleased to warmly welcome Stina Wallmark to our team. With her strong industry expertise, we’re excited to continue supporting companies that push the boundaries of scaling innovation in health.”
Why Life Sciences?
Stina Wallmark sees immense potential in life sciences to address critical global challenges, including the increasing demand for healthcare driven by Europe’s ageing population. “Life Sciences brings together all the elements on the cutting edge of bio-innovation,” she explains. “It’s not only about advancing healthcare and developing new treatments but also tackling broader issues—breakthroughs in biology can impact food security, clean energy, and beyond.”
Wallmark emphasises that the field needs more than just traditional therapies. “We need tools to support the entire healthcare workflow, from predictive health diagnostics to smarter, faster therapy innovation,” she says. “Ultimately, I want to help create a better world for my children and future generations by supporting impactful, real-world solutions.”
Leveraging Nordic Strength in Life Sciences
With offices in Finland and Sweden, Voima Ventures is well-positioned to capitalise on the Nordics’ strengths in Life Sciences. Jenny Engerfelt, Swedish Partner at Voima Ventures, adds, “We’re seeing remarkable work in Sweden and Denmark, from combating antibiotic resistance to AI-driven diagnostics and drug discovery. These innovations are not only timely but essential in driving the future of healthcare leading to a positive impact for both people and industries. Stina’s strategic insight and connections within the Nordic life sciences ecosystem will enhance Voima Venture’s ability to identify and support high-impact startups in healthcare and biotech.”
The Future Of Innovation In Health X
Voima Ventures, through its Article 8-compliant Fund III, is dedicated to supporting companies that drive positive environmental, economic, and societal impact. “We’re at a thrilling juncture where fields like organic chemistry and synthetic biology are intersecting in unprecedented ways,” says Wallmark. “In the near future, diagnostics might even start with something as simple as a smartphone sensor analysing your breath. As science advances, our focus is on investing in teams whose innovations have the potential to make measurable improvements in global health outcomes.”
Originally published on 7 November by Voima Ventures.
Announcements are published as a service to readers. The sender is responsible for all content.
Announcements for publication can be submitted to [email protected].
